Compare BridgeBio Pharma Inc (BBIO) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Target Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Target Corporation trades at $151.85 (market cap $69.17B). The key difference: Target Corporation is far larger — about 4.2× BridgeBio Pharma Inc's market cap, and Target Corporation pays a 3.05% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TGT | |
|---|---|---|
Market Cap | $16.36B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $152.35 |
52-Week Low | $47.29 | $83.68 |
Enterprise Value | $18.14B | $84.47B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
Target (TGT) trades at $152.09, up 1.6% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Valuation metrics show a P/E of 20.12 and P/S of 0.65, while profitability remains solid with a 22.02% ROE. Recent news highlights the appointment of a Chief AI Officer, signaling strategic focus on technology.
The outlook for TGT is positive, driven by earnings momentum and AI initiatives, but risks include competitive retail pressures and potential margin compression. Analyst consensus is mixed with a $147.72 price target, suggesting limited upside from current levels, though institutional buying activity supports bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
